Press releases

ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

ORYZON to give updates on corporate progress in September

ORYZON collaborates with the CMT Research Foundation in the US

ORYZON reports results and corporate update for half-year ending June 30, 2022

ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers

ORYZON announces a New Financing through a Convertible Bond Program for a Total amount up to €20 Million over 30 months

ORYZON at EHA-2022: iadademstat 42-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Small Cell Lung Cancer

ORYZON awarded EU Seal of Excellence and public financing of 2 M USD to develop iadademstat in Acute Myeloid Leukemia

ORYZON to give updates on corporate progress in June